fbpx
  1. Home
  2. »
  3. Pandemic Pulse
  4. »
  5. FDA Schedules Public Meeting on Long COVID

FDA Schedules Public Meeting on Long COVID

Facebook
Twitter
LinkedIn
Print
To better understand and address the impacts of long COVID, the U.S. Food and Drug Administration (FDA) is hosting a public meeting on April 25, 2023 to hear directly from patients and patient representatives.

To better understand and address the impacts of long COVID, the U.S. Food and Drug Administration (FDA) is hosting a public meeting to hear directly from patients and patient representatives. The meeting will provide an opportunity for patients to discuss how long COVID affects their daily life, common symptoms they experience, current approaches to treatment, and factors they consider when determining whether or not to participate in a clinical trial. The FDA will also be accepting written comments on these subjects. Additional information can be found in the Federal Register.

This is a great opportunity for long COVID patients to directly share their experiences with the FDA and help inform the development of treatments and clinical trials. The public meeting will be held on April 25, 2023 from 10am-4pm ET. A live webcast of the public meeting will be available. Register now to attend the meeting.

In collaboration with the COVID-19 Health and Safety Taskforce, Pandemic Patients is soliciting feedback from people with long COVID that will be incorporated into the organization’s written comments to the FDA. Complete our survey to ensure that your experiences are reflected in our submission to the agency!

CHeST Endorses the Stop the Wait Act

CHeST is proud to announce its endorsement of the Stop the Wait Act (H.R. 883 and S. 320), which seeks to end the 5-month waiting period for individuals to receive Social Security Disability Insurance (SSDI) benefits, as well as allow those who are uninsured or unable to afford insurance during the 29-month waiting period for Medicare to receive coverage.